In Phase A, individuals will acquire various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals will be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "insert-on" therapy. In Phase C, https://abbv-744-brd4-inhibition80235.blogsidea.com/38360465/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets